Biotech VC hits $9.1B in H1 but preclinical funding gap deepens

For the biotech and pharma industry, the headline $9.1 billion VC haul obscures a dangerous imbalance: the pipeline that will deliver tomorrow's therapies is being starved of early-stage capital. As regulatory headwinds persist and geopolitical risks mount, the widening gap between clinical success and discovery funding could reshape therapeutic focus areas and deal structures for years to come.

Biotechnology venture capital funding surged in the first half of 2026, with 68 startups raising a combined $9.1 billion — the highest first-half total since 2022. This robust headline figure, however, conceals a widening funding gap: the vast majority of these companies already had drug candidates in clinical testing, while preclinical and discovery-stage biotechs face an increasingly arid fundraising environment. Data compiled by BioPharma Dive show that 76% of the total haul came from 'megarounds' of $100 million or more, a sign that later-stage, de-risked assets are absorbing disproportionate capital. The trend is fueled by a buoyant public market, where 13 biotech IPOs have already raised $4.5 billion in 2026, with a median haul of nearly $302 million — figures unusually high by historical standards. Two companies, Parabilis Medicines and Kailera Therapeutics, shattered sector records. Most newly public biotechs are trading above their offer prices, reinforcing investor appetite for clinical-stage narratives. Mergers and acquisitions have also accelerated dramatically, with 38 deals struck year-to-date, nearly two-thirds of which involved $1 billion or more. This dealmaking pace puts 2026 on track to be the busiest acquisition year in at least seven years, providing lucrative exit paths for late-stage investors and further concentrating capital in assets close to market.

“

Data compiled by BioPharma Dive show that 76% of the total haul came from 'megarounds' of $100 million or more, a sign that later-stage, de-risked assets are absorbing disproportionate capital.

Yet the vibrancy at the top obscures distress at the bottom. Ben Zercher, senior analyst at PitchBook, noted that venture capital has 'continued to go strong' despite headwinds such as a potential U.S. crackdown on investments in Chinese drug assets and ongoing turmoil at the FDA. His comment, however, reflects the perspective of funds deploying into later-stage rounds, not the seed-stage reality. Early-stage biotech founders must navigate the same regulatory uncertainties but without the cushion of validated clinical data or clear exit timelines. The result is a bifurcated ecosystem: one segment enjoys record valuations, smooth IPO pathways, and active M&A interest; the other struggles to raise any venture funding at all, leading to startup attrition and potentially a weaker drug pipeline in the 2030s.